Abstract Number: 815 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. PALACE 2 compared the efficacy and safety of APR…Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…Abstract Number: 817 • 2013 ACR/ARHP Annual Meeting
Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
Background/Purpose: Psoriasis-associated skin and joint disorders are characterized by ongoing inflammation mediated by similar molecular pathways. IL-17 plays a potential role in the pathogenesis and…Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting
HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis
Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton. Little is known about the clinical predictors of sacroiliitis (SI),…Abstract Number: 819 • 2013 ACR/ARHP Annual Meeting
Low Diagnostic Utility Of Candidate Definitions For a Positive MRI Of The Spine In Axial Spondyloarthritis
Background/Purpose: A recent consensus statement based on a systematic literature review by the Assessment of SpondyloArthritis International Society suggested the presence of ≥3 corner inflammatory…Abstract Number: 820 • 2013 ACR/ARHP Annual Meeting
CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disease in which B cells may play a crucial role in pathogenesis. CC-220 is an immunomodulatory drug…Abstract Number: 821 • 2013 ACR/ARHP Annual Meeting
Activation Of The Signal Transducer and Activator Of Transcription 3 By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by uncontrolled activation of fibroblasts resulting in tissue fibrosis in which the TGFβ signaling plays a main role. Signal…Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…Abstract Number: 824 • 2013 ACR/ARHP Annual Meeting
Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli1 Knockout Mice By Increasing The DNA Binding Ability Of Fli1 – a Possible Mechanism Explaining The Effect Of Bosentan On Scleroderma Vasculopathy
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although there…Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…Abstract Number: 826 • 2013 ACR/ARHP Annual Meeting
The Value Of History and Physical Examination Findings In The Diagnosis Of Symptomatic Meniscal Tear Among Middle-Age Subjects With Knee Pain
Background/Purpose: Clinicians often rely on mechanical symptoms (e.g. clicking, catching, popping, giving way) and tests such as the McMurray sign in the diagnosis of symptomatic…Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…Abstract Number: 788 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients
Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard immunosuppressive drugs and it may require biological therapy. Tocilizumab (TCZ) has demonstrated efficacy in clinical…Abstract Number: 789 • 2013 ACR/ARHP Annual Meeting
Sirolimus Plus Prednisone For Erdheim-Chester Disease: A Pilot Trial
Background/Purpose: Erdheim-Chester disease (ECD) is an extremely rare form of non-Langerhans cell histiocytosis. The pathogenesis of ECD is unclear: while most authors suggest the hypothesis…